Company runs afoul of NASDAQ listing requirementsShares in imaging services provider U.S. Diagnostic of West Palm Beach, FL, took a tumble this month after it delayed the release of its first-quarter financial results and announced that it had
Company runs afoul of NASDAQ listing requirements
Shares in imaging services provider U.S. Diagnostic of West Palm Beach, FL, took a tumble this month after it delayed the release of its first-quarter financial results and announced that it had been notified that it did not comply with listing requirements on the NASDAQ stock exchange. USDL's stock recovered somewhat once the first-quarter results were released, however, and USDL executives say they are working to resolve the listing-requirements issue.
USDL's stock fell 25% to close at $6 a share on May 16, the day after it reported the NASDAQ notification and the request for a filing extension. The quarterly filing delay was related to the process of USDL auditing and restating its 1996 financial reports, according to president and CEO Joseph Paul.
"We had to restate our 1996 10-Qs," he said. "Part of the delay in filing the 1997 10-Q was that we had to file the 1996 first-quarter report before we could do the 1997 report."
Adding to shareholder anxiety, USDL said it had been told by NASDAQ that it did not comply with the exchange's net tangible asset requirements for the NASDAQ National Market System.
Paul said the notification was not a sign of financial distress at the company. USDL's current deficit in net tangible assets is uniform with many operations that are aggressively involved in mergers and acquisitions, he said. Moreover, NASDAQ seems to recognize that a high level of good will (or excess of prices paid over the value of tangible assets purchased) does not necessarily indicate financial trouble.
"In this industry, what you are buying is cash flow. We spent about $200 million in cash and stock in 1996 to buy companies that had net assets of about $50 million. That created approximately $150 million of good will," he told SCAN. "On our balance sheet, we have approximately $137 million in shareholders' equity. We have $157 million in good will. That creates the $20 million negative."
Shareholder concerns were assuaged somewhat once USDL released its 1997 first-quarter (end-March) results on May 20. Net revenues for the first quarter were $52.5 million, quadruple the level of $12.6 million in the same quarter of 1996. First-quarter net income was $2 million, which doubled last year's $1 million for the first quarter. The company's stock subsequently rebounded somewhat and closed at $7.25 on May 21.
USDL is getting back on its feet after a turbulent first five months of 1997, Paul said. While the firm won't likely approach the stock market for funding this year, financing is available that should enable USDL to add another 25 to 50 imaging centers over the remainder of 1997 to its current 120-center network.
USDL established a $50 million credit facility with DVI of Doylestown, PA, in February for use in acquisitions. The company is arranging for bank financing to add to this pool, he said.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.